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Introduction: Accurate determination of ALK rearrangement is
important in lung cancer patients, especially in determining their
eligibility for crizotinib therapy. Fluorescence in situ hybridization
(FISH) has been regarded as the gold standard method for detecting
ALK rearrangement. However, FISH requires a fluorescence micro-
scope, and the signals are labile and rapidly fade over time. This
study evaluates the concordance between ALK gene rearrange-
ment in non-small cell lung cancer assessed by ALK FISH and a
newly developed ALK chromogenic in situ hybridization (CISH)
and correlates the results with ALK protein expression assessed
by immunohistochemistry.
Methods: A total of 465 formalin-fixed, paraffin-embedded non-
small cell lung cancer samples were analyzed by ALK FISH (Path-
Vysion, Vysis, Abbott) and ALK CISH. For comparison, all speci-
mens were stained by immunohistochemistry (clone 5A4,
Novocastra) and interobserver reproducibility was assessed.
Results: We found that agreement between the pathologists on the
CISH-determined ALK status was achieved in 449 patients (96.6%),
and ALK rearrangement was identified in 18 patients (4.0%) in CISH
method. Among these cases, 443 cases (95.3%) had results matching
the corresponding FISH results: 17 rearranged, 425 wild types, and
1 discordant case. There was high concordance in the assessment of
ALK gene rearrangement between FISH and CISH techniques ( 
0.92) and between observers (  0.97). In addition, there was high
concordance in the ALK gene status and ALK protein expression
between CISH and IHC tests (  0.82).
Conclusions: CISH is a highly reproducible and practical method to
detect ALK gene rearrangement and correlated well with ALK protein
expression. Here, we present a diagnostic algorithm (Chung’s SNUBH
ALK protocol) to detect lung cancer with ALK rearrangements using
IHC, FISH and CISH. Because CISH allows a concurrent analysis of
histological features of the tumors and gene rearrangement, it appears to
be a useful method in determining ALK gene rearrangement.
Key Words: Lung cancer, ALK, Fluorescence in situ hybridization,
Chromogenic in situ hybridization.
(J Thorac Oncol. 2011;6: 1359–1366)
The fusion of anaplastic lymphoma kinase (ALK) gene withthe echinoderm microtubule-associated protein-like 4
(EML4) gene was identified recently in non-small cell lung
cancer (NSCLC).1 ALK is a receptor tyrosine kinase described
in anaplastic large cell lymphoma with t(2;5)(p23;q35) resulting
in nucleophosmin (NPM)-ALK fusion protein. The ALK-
signaling pathway includes several biologically important
pathways involving cell proliferation, differentiation, and
antiapoptosis.2 In NSCLC, the frequency of the EML4-ALK
fusion gene is about 3 to 6.7%.2–7 A novel ALK tyrosine
kinase inhibitor named crizotinib (PF-02341066) is currently
in phase II and III clinical trials for advanced NSCLC with
ALK rearrangement, and early reports have demonstrated
dramatic clinical responses in ALK-rearranged NSCLC pa-
tients assessed by fluorescence in situ hybridization (FISH).8,9
Accurate and rapid screening of ALK rearrangement is important
in NSCLC patients, especially in determining their eligibility for
crizotinib therapy. Because rearrangement of the ALK gene
appears to be the mechanism underlying the overexpression of
its gene product, immunohistochemistry (IHC) can be a screen-
ing method to detect gene rearrangement.10
In principle, there are two approaches to determine the
ALK status: detection of the protein overexpression by IHC
and gene rearrangement by in situ hybridization (ISH). Both
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have advantages and disadvantages; quantification of IHC is
difficult, whereas ISH enables the pathologist to perform a
more reliable quantification of the genomic alteration. FISH
has been regarded as the gold standard method for detecting
ALK rearrangement. However, the disadvantages of deter-
mining ALK rearrangement by FISH are that the fluorescent
signal rapidly fades over time, and a fluorescence microscope
is needed for interpretation, which is not usually done in
clinical routine works. Another problem is that it is difficult
to detect the overall morphology and tumor heterogeneity
with FISH technology.11 Furthermore, despite many attempts
to improve accuracy of ALK testing in routine practice,
several recent publications have addressed discordances be-
tween FISH and IHC assays.5
Chromogenic in situ hybridization (CISH) for ALK
gene rearrangement detection is a method newly developed
by two of the authors (H.N. and T.M.G.) which may over-
come many of the disadvantages of FISH as it allows the
quantification of the signals by conventional bright field light
microscopy.12 In addition, CISH is a fully automated bright
field ISH assay and provides stable and permanent archival
slides that are evaluable with conventional bright field light
microscopy.13,14 In this study, the ALK gene rearrangement
status of 465 consecutive NSCLC cases was examined in
parallel by FISH and CISH and correlated with protein
expression by IHC. For validation and comparison of the
genetic assays (CISH versus FISH) and to determine inter-
observer variability, a panel of two pathologists (K.H. and
Y.S.B.) read and scored the slides independently.
The aims of this study were (1) to evaluate the concor-
dance between ALK CISH and FISH assay in determining the
status of ALK rearrangement; (2) to assess the interobserver
interpretative reproducibility; and (3) to correlate CISH with
protein expression by IHC.
PATIENTS AND METHODS
Patient Samples
Formalin-fixed, paraffin-embedded (FFPE) NSCLC
specimens from 465 patients diagnosed at Seoul National
University Bundang Hospital from May 2003 to May 2008
were included in this study. All cases were diagnosed as
primary lung origin on review of the medical records. The
465 cases of NSCLC were classified according to the 2004
WHO classification.15 The cohort consisted 269 cases of
adenocarcinoma (ADC), 169 cases of squamous cell carci-
noma (SCC), 10 cases of adenosquamous carcinoma (ASC),
5 cases of pleomorphic carcinoma (PLC), 2 cases of large cell
carcinoma (LCC), 8 cases of large cell neuroendocrine car-
cinoma (LCNEC), 1 case of carcinosarcoma (CS), and 1 case
of lymphoepithelioma-like carcinoma (Table 1). No patients
had received any therapy before surgery. This study was
approved by the Institutional Review Board at Seoul National
University Bundang Hospital.
Construction of Tissue Microarray
Representative core tissue sections (diameter 2 mm)
were obtained from individual NSCLC tissue (donor blocks)
and arranged in new recipient paraffin blocks (tissue array
blocks) as previously described.16 Three semiserial sections
were cut and examined for the ALK status by IHC, FISH, and
CISH assays.
TABLE 1. Clinicopathologic Characteristics Related CISH and FISH
Variables
ALK CISH
p
ALK FISH
p   
Total 18 (4.0%) 431 (96.0%) 19 (4.2%) 434 (95.8%)
Sex
Male 12 (66.7%) 294 (68.2%) NS 11 (57.9%) 298 (68.7%) NS
Female 6 (33.3%) 137 (31.8%) 8 (42.1%) 136 (31.3%)
Age (yr)
65 5 (27.8%) 220 (51.0%) NS 6 (31.6%) 224 (51.6%) NS
65 13 (72.2%) 211 (49.0%) 13 (68.4%) 210 (48.4%)
Smoking habit
Never 9 (50.0%) 160 (37.1%) NS 10 (52.6%) 161 (37.1%) NS
Smoker 9 (50.0%) 271 (62.9%) 9 (47.4%) 273 (62.9%)
Histology
ADC 17 (94.4%) 245 (56.8%) 0.001 18 (94.7%) 245 (56.5%) 0.001
SCC 0 160 (37.1%) 0 163 (37.5%)
Others 1 (5.6%) 26 (6.1%) 1 (5.3%) 26 (6.0%)
p-stage
I 8 (44.4%) 190 (44.1%) NS 8 (42.1%) 190 (43.8%) NS
II–IV 10 (55.6%) 241 (55.9%) 11 (57.9%) 244 (56.2%)
Total 449 453
CISH, chromogenic in situ hybridization; FISH, fluorescence in situ hybridization; ADC, adenocarcinoma; SCC, squamous cell carcinoma; NS,
not significant.
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Fluorescence In Situ Hybridization
FISH assay was performed on FFPE tumor tissues
using a break-apart ALK probe that hybridizes to the band
2p23 with SpectrumOrange (red) and SpectrumGreen on
either side of the ALK gene breakpoint (Vysis LSI ALK
dual-color, break-apart rearrangement probe; Abbott Molec-
ular, Abbott Park, IL) according to the manufacturer’s in-
structions. Briefly, 3-m-thick sections from FFPE tissue
blocks were deparaffinized, dehydrated, immersed in 0.2N
HCl, and washed. The sections were immersed in 0.01M
citrate buffer (Abbott Molecular), boiled in a microwave for
5 minutes, treated with pretreatment reagent (Abbott Molec-
ular) at 80°C for 30 minutes, and reacted with protease mixed
with protease buffer (Abbott Molecular). After applying the
probe mixture onto the tissue sections, sealed slides were
incubated in a humidified atmosphere with Hybrite (Abbott
Molecular) at 75°C for 5 minutes to denature the probe and
target DNA and sequentially incubated at 37°C for 16 hours
to allow hybridization. Then they were immersed in 0.3%
NP-40 (Abbott Molecular)/2 saline sodium citrate for wash-
ing. For nuclear counterstaining, 4,6-diamidino-2-phenylindole
(DAPI) II with antifade compound p-phenylenediamine was
applied. Signals for each probe were evaluated under a micro-
scope equipped with a triple-pass filter (DAPI/Green/Orange;
Abbott Molecular) and an oil immersion objective.
There were two positive ALK rearrangement patterns.
One was the break-apart (BA) pattern with one fusion signal
(native ALK) and two separated orange and green signals.
The distance between two separated signals was estimated
using the two times of biggest signal size.17 Another was
isolated red signal (IRS) pattern with one fusion signal
(native ALK) and one red signal without corresponding green
signal. The positive cases were defined as more than 15% BA
or IRS in 50 tumor cells as previously described.10,17
Chromogenic In Situ Hybridization
ALK dual-color break-apart CISH was performed as
described previously.12 Briefly, NSCLC slides were deparaf-
finized with EZ Prep (Ventana Medical Systems, Inc., Tuc-
son, AZ) and Liquid Coverslip (LCS) (Ventana Medical
Systems, Inc.). Then for DNA target retrieval, heat treatment
with 1 Reaction Buffer (Ventana Medical Systems, Inc.)
followed by protease digestion with ISH Protease 2 (Ventana
Medical Systems, Inc.) for 8 minutes. Digoxigenin (DIG)-
labeled 5 ALK probe and 2,4 dinitrophenyl (DNP)-labeled
3 ALK probe were cohybridized at 44°C for 5 hours after
denaturing at 85°C for 20 minutes. Stringency wash was
conducted at 72°C with 2 SCC (Ventana Medical Systems,
Inc.). DIG hapten was visualized with fast blue detection after
incubation with mouse anti-DIG antibody and alkaline phos-
phate (AP)-conjugated goat anti-mouse antibody. The AP
enzyme was inactivated with a hybridization buffer for 32
minutes at 37°C. DNP hapten was visualized with fast red
detection after incubation with rabbit anti-DNP antibody and
AP-conjugated goat anti-rabbit antibody. After CISH detec-
tion was completed, all slides were counterstained with He-
matoxylin II (Ventana Medical Systems, Inc.) and Bluing
Reagent (Ventana Medical Systems, Inc.). The criteria for
positivity in CISH were the same as in FISH.
Immunohistochemistry
FFPE tissues were sectioned at 4-m thickness and
stained using Ventana automated immunostainner (Ventana
Medical Systems, Inc.) according to the manufacturer’s pro-
tocol. Briefly, the slides were dried at 60°C for 1 hour and
deparaffinized using EZ Prep (Ventana Medical Systems) at
75°C for 4 minutes. Cell conditioning (heat pretreatment) was
performed using CC1 solution containing Tris/Borate/EDTA
at 100°C for 20 minutes. Antibody for ALK (mouse mono-
clonal, clone 5A4) (Novocastra, Newcastle, UK) was diluted
to 1:30, treated, and incubated at 42°C for 2 hours. Signals
were detected using i-view detection kit (Ventana Medical
Systems) based on the labeled streptavidin-biotin (LSAB)
method. Each step of the kit included the treatment of inhibitor
(1%H2O2) (4 minutes), biotinylated Ig (8 minutes), streptavidin-
horseradish peroxidase (8 minutes), DAB (chromogen  sub-
strate) (8 minutes), and copper (4 minutes) at 37°C. Counter-
staining was performed with Mayer’s hematoxylin (ScyTek,
Logan, UT) for 2 minutes at room temperature.
Semiquantitative assessment was done by estimating
the staining intensity and percentage of tumor cells with
positive cytoplasmic staining. Each cell was first scored as 0,
1, 2, or 3, which corresponded to negative, weak, moderate,
and strong staining intensities, respectively. ALK IHC scores
were assigned as follows: 0  no stained cells; 1  faint or
weak staining intensity with 5% tumor cells or any staining
intensity with 5% tumor cells; 2  moderate staining
intensity with 5% tumor cells; 3  strong and granular
staining intensity with 5% tumor cells.10 Although ALK
IHC score 1 was hardly discernable in the low-power objec-
tive lens (under objective lens 10), ALK IHC scores 2 and
3 were readily identifiable. Increases in the staining intensity
were associated with increases in the number of positively
stained cells observed: a staining intensity of 1 resulted in an
average of 14.7% positively stained cells, a staining intensity
of 2 resulted in 58.2% positively stained cells, and a staining
intensity of 3 resulted in 97.3% positively stained cells.
Statistical Analysis
Accordance between FISH and CISH, and IHC and
CISH was analyzed using kappa () statistics. Analyses were
performed using SPSS version 18.0 (SPSS Inc., Chicago, IL).
RESULTS
Clinicopathologic Characteristics
A total of 465 consecutively resected NSCLC samples
were examined. ALK rearrangement was determined in 453
patients (97.4%) by FISH and 449 patients (96.6%) by CISH.
There were 12 and 16 cases not evaluable in FISH and CISH,
respectively. Reasons for failure were complete detachment
of tissues or unrecognizable ISH signal. Clinicopathologic
features and ALK CISH and FISH results are shown in Table
1. The mean age of the 465 patients was 63.8 years and
ranged from 21 to 84 years. ALK CISH results were similar to
ALK FISH as previously described.10 ALK-positive cases had
predominantly ADC histology. ALK-positive patients showed
no statistical difference in gender, age, or smoking history
compared with ALK wild-type patients.
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ALK Rearrangement Assessed by CISH
ALK rearrangement was assessed using CISH in 449
patients (96.6%), and ALK rearrangement was identified in 18
patients (4.0%). The majority of the ALK CISH-negative
cases showed two fusion signals (purple-colored signals) or
close proximity of the red and blue signals less than two
signal size. A few cells demonstrated an isolated blue signal
(IBS) with loss of the corresponding red signal. An indepen-
dent blue signal corresponds to no rearrangement, whereas a
red signal corresponds to rearrangement associated with the
tyrosine kinase domain. The clinical significance of IBS is
unknown.
The ALK CISH-positive NSCLC cases showed two
major patterns using the ALK dual-color break-apart probe as
follows: (1) the break-apart (split) pattern was observed in
72.2% of cases (13/18) (Figure 1C) and (2) IRS pattern: the
isolated (single) red signal was predominant in 27.8% of
cases (5/18) (Figure 1D).
ALK Gene Status in the Normal Tissue by CISH
Most normal lymphocytes, stromal cells, bronchiolar
epithelial cells, or alveolar pneumocytes showed one or two
blue, red signals or fused purple signals. The red and blue
signals were colocalized and produced overlapping purple
dots or close proximity less than two signal size distance. It
should be noted that there were a few cells showing IBS or
IRS in the lymphocytes. As in FISH or CISH tests on tissue
sections, most of the cells are partially included within a
tissue section due to nuclear truncation, and a few IBS or IRS
might be artifacts due to sectioning process. It was more
obvious for CISH method rather than FISH method because
CISH permits easier distinction of tumor cells from normal
tissue. The incidence of BA or IBS in the normal tissue was
rare, but exact evaluation was impossible due to paucity of
normal cells in the TMA.
ALK Rearrangement Assessed by FISH10
ALK rearrangement was assessed using FISH in 453
patients (97.4%), and ALK rearrangement was identified in 19
patients (4.2%). The majority of the ALK FISH-negative
cases showed two fusion signals or close proximity of the red
and green signals. However, a few cells demonstrated an
isolated green signal (IGS) with loss of the corresponding red
signal. An independent green signal corresponds to no rear-
rangement, whereas a red signal corresponds to rearrange-
ment associated with the tyrosine kinase domain. The clinical
significance of IGS is unknown.
The ALK FISH-positive NSCLC cases showed two
major patterns using the LSI ALK dual-color break-apart
probe as follows: (1) the break-apart (split) pattern was
observed in 73.7% of cases (14/19) (Figure 1A) and (2) IRS
pattern: the isolated (single) red signal was predominant in
26.3% of cases (5/19) (Figure 1B). The interobserver agree-
ment between pathologists was excellent (  0.94).
Comparison between CISH and FISH
ALK rearrangement was identified in 19 and 18 patients
by FISH and CISH, respectively. There was high concor-
dance in the assessment of ALK gene rearrangement between
CISH and FISH results ( 0.92) (Table 2). When FISH was
chosen as the gold standard, the sensitivity of CISH was
94.4% and specificity 100% (positive predictive value 100%,
negative predictive value 99.8%). There was only one dis-
cordant case in results between FISH and CISH. The discrep-
ant case showed break-apart signals at a distance of the two
times of biggest signal size in FISH. However, the distance of
FIGURE 1. ALK gene rearrange-
ment pattern by fluorescence in situ
hybridization (FISH) (A and B, 100)
and chromogenic in situ hybridiza-
tion (CISH) (C and D, 63); two dis-
tinct red and green (break-apart)
signals and one intact fusion signal
in FISH (A); two distinct red and blue
(break-apart) signals and one intact
fusion signal in CISH (C); an isolated
red signal (IRS) and one intact fusion
signal in FISH and CISH, respectively
(B and D).
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split signal was closer and estimated less than two signal size
in CISH. Furthermore, tumor portion showing gene rear-
rangement (16% by FISH and 14% by CISH) was borderline
to interpret as positive. So, we interpreted this case as
negative in CISH.
The ALK rearrangement cases showed two major pat-
terns including BA and IRS. Regarding the rearrangement
pattern, there was perfect concordance in BA and IRS pat-
terns between the two methods (  1.00, Table 3).
Concordance between CISH and IHC
ALK protein expression was detected in 8.6% (40/465)
of the NSCLC cases, which included scores of 0 (n  425),
1 (n  14), 2 (n  10), and 3 (n  16) as previously
described.10 To evaluate the correlation of IHC assessment to
predict gene rearrangements, we compared the ALK results
using IHC and CISH (Table 4). The average percentage of
cells positively stained using IHC was higher in the CISH-
positive tumors than in the CISH-negative tumors (92.4%
versus 19.3%). All the cases with CISH-positive tumors were
IHC score 3 or 2, and all the cases with IHC scores 0 or 1
were CISH negative (Figure 2). For cases with scores of 2,
30% (3/10) were CISH positive and 70% (7/10) were CISH
negative.
IHC-positive (3) cases showed CISH positive in
89.5% (14/16) and CISH negative in 5.25% (1/16). The one
case with IHC score 3 (5.25%) was not evaluable by CISH
test due to diffusion of signal. When IHC scores of 2 and
3 were regarded as positive and scores of 0 and 1 were
regarded as negative, there was high agreement between
CISH and IHC results (  0.82).
There was one case with IHC score 3, which were
discordant with CISH results. This case was considered as
positive by FISH but the BA signal percentage was borderline
and considered as CISH negative (16% by FISH and 14% by
CISH). Furthermore, the BA signal distance was insufficient,
and interobserver variability was present.
Assuming that ALK IHC scores of 0 and 1 were ALK
rearrangement-negative, an ALK IHC score of 3 was ALK
rearrangement-positive, and an ALK IHC score of 2 was
equivocal, the results of the ALK IHC assay using the tiered
scoring method and CISH were strongly correlated (p 
0.001) (Figure 3).
Interobserver and Intraobserver Agreement
of CISH
Tables 5 and 6 showed the results of CISH evaluation
between each observer and intraobserver comparison. Two
pathologists (H.K. and S.B.Y.) evaluated 449 cases excluding
inadequate cases independently. The overall interobserver
agreement was 99.7% (  0.97) (Table 5). Discordant
results were observed in 1 of the 449 cases. In that case, the
distance between two separate signals was insufficient and
borderline positivity of tumor proportion. One pathologist
(H.K.) interpreted it as negative, whereas the other (S.B.Y.)
interpreted it as positive for ALK rearrangement (positive in
16% of tumor cells) and the latter corresponded with the
FISH result. To make a consensus, repeated interpretation
was performed ( 0.97) (Table 6). The complete agreement
was made for negative cases, but the disagreement was found
in one case that was interpreted as negative at first observa-
tion, however, as positive at second observation due to
borderline tumor portion showing ALK rearrangement.
DISCUSSION
In this study, the authors introduced newly developed
method for the detection of ALK rearrangement by dual-color
CISH, and the results showed an excellent concordance
between CISH and FISH. We also established optimal con-
dition of IHC for ALK protein expression, which corre-
sponded well with the gene rearrangement results evaluated
by CISH and FISH (Figure 3).10 To the best of our knowl-
edge, this is the first report to compare the accuracy of CISH
with FISH results for ALK gene rearrangement and to corre-
late CISH results with ALK protein expression by IHC.
Previous studies have shown good correlation between CISH
and FISH assays to determine EGFR status in NSCLC,
although the CISH tests used were single-colored probe.11,18
However, ALK gene rearrangement status has not been ex-
TABLE 2. Comparison of ALK Status between FISH and CISH
CISH
FISH
TotalPositive Negative Not Applicable
Positive 17 (89.5%) 0 1 (8.3%) 18
Negative 1 (5.25%) 425 (97.9%) 5 (41.7%) 431
Not applicable 1 (5.25%) 9 (2.1%) 6 (50.0%) 16
Total 19 434 12 465
  0.92 (0.75, excellent; 0.4–0.7, good; 0.4, poor agreement).
CISH, chromogenic in situ hybridization; FISH, fluorescence in situ hybridization.
TABLE 3. Comparison of ALK Rearrangement Pattern
between FISH and CISH
CISH Positive
FISH Positive
TotalBA IRS
BA 12 (100%) 0 12
IRS 0 5 (100%) 5
Total 12 5 17
  1.00 (0.75, excellent; 0.4–0.7, good; 0.4, poor agreement).
CISH, chromogenic in situ hybridization; FISH, fluorescence in situ hybridization;
BA, break-apart; IRS, isolated red signal.
TABLE 4. Comparison of ALK Status Between IHC and CISH
CISH
IHC
Total3 2 0/1
Positive 14 (87.5%) 3 (30.0%) 0 17
Negative 1 (6.25%) 7 (70.0%) 423 (100%) 431
NA 1 (6.25%) 0 0 1
Total 16 10 423 449
  0.82 (0.75, excellent; 0.4–0.7, good; 0.4, poor agreement).
CISH, chromogenic in situ hybridization; IHC, immunohistochemistry; NA, not
applicable.
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amined in parallel by FISH and CISH. Our results showed an
excellent concordance between CISH and FISH. We also
observed a significant correlation of ALK protein expression
and gene status between CISH/FISH and IHC. Our findings
suggest that CISH is a reliable and appropriate method for
detecting ALK gene status in NSCLC.
There was one discrepant case between CISH and FISH
results that showed BA pattern ALK rearrangement in FISH
but negative in CISH (Table 2). This case was interpreted
positive by one pathologist, which showed disagreement in
interobserver comparison (Table 5). The discrepancy may
result from uncertain criteria of ALK rearrangement: (1)
insufficient distance between separate signal, (2) different
signal size between FISH and CISH probes, and (3) 15%
criteria showing ALK gene rearrangement. First, the distance
FIGURE 2. Comparison between
immunohistochemical (IHC) stain-
ing patterns (40) and chromo-
genic in situ hybridization (CISH)
patterns (63). ALK IHC 3 tumor
cells (A) showed ALK gene rear-
rangement in CISH (B); ALK IHC
2 tumor cells (C) also showed
ALK gene rearrangement in CISH
(D); ALK IHC 1 tumor cells (E)
also showed native ALK gene status
(no ALK gene rearrangement) (F).
FIGURE 3. Chung’s SNUBH ALK protocol presents sche-
matic diagram to predict ALK gene rearrangement by IHC.
IHC, immunohistochemistry, CISH, chromogenic in situ hy-
bridization, FISH, fluorescence in situ hybridization.
TABLE 5. Interobserver Variation of CISH Result
Observer 2
Observer 1
TotalPositive Negative
Positive 18 (100%) 1 (0.2%) 19
Negative 0 430 (99.8%) 430
Total 18 431 449
  0.97 (0.75, excellent; 0.4–0.7, good; 0.4, poor agreement).
CISH, chromogenic in situ hybridization.
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between separate signals is estimated using the signal size as
a reference, and the probes separated by at least 8 MB can be
readily detected with high sensitivity and specificity in par-
affin-embedded tissues.17 This is the reason that analyses
must be performed by experienced person. Although the use
of bright field microscopy in automated CISH assay is more
helpful to recognize the distance of separate two signals,
there was still discordance related to the insufficient separate
distance using break-apart probe. Second, because the signal
size of CISH is bigger than that of FISH, two signal size
distances in CISH may be separated far away compared with
FISH. Because ALK gene translocation analyses using CISH
is a newly developed method, further studies are required for
setting up an appropriate cutoff value for break-apart distance.
Finally, although previous studies including the ongoing crizo-
tinib trials used the 15% cutoff value for ALK rearrangement-
positive reading criterion,8,9 it appeared to be arbitrary. It is
important to consider a negative control, such as normal non-
neoplastic lung tissues, for establishing a cutoff value for accu-
rate FISH or CISH interpretation. We observed that most of the
FISH-positive cases showed abnormal split or isolated red signal
in more than 50% of tumor cells. Although there was a discrep-
ant case showing borderline positivity around 15% in both FISH
and CISH test, it would be necessary to confirm the ALK status
using another method such as reverse transcription-polymerase
chain reaction (RT-PCR).
An accurate, reliable, and reproducible method for
determining ALK rearrangement is essential for identifying
NSCLC patients who are candidates for treatment with an
ALK inhibitor named crizotinib, which has shown significant
response in NSCLC patients with ALK rearrangement.3,4,8,9,17
FISH has been universally accepted as a reference standard in
the assessment of ALK rearrangement.8 However, FISH re-
quires a fluorescence microscope, and the signals are labile
and rapidly fade overtime. For these reasons, several bright
field ISH methods have been developed as a potential alter-
native to FISH.12–14 CISH allows detection of gene copy
status using a conventional peroxidase-base reaction and
standard bright field light microscope.18–20 However, the
characteristics of the CISH method are not absolutely ideal:
the signals appeared somewhat diffuse and bigger than those
of FISH, which can make quantification difficult, and signals
can be difficult to distinguish from nuclear counterstains.
The introduction of an effective and widely applicable
screening method using IHC to detect NSCLC with ALK
rearrangement is essential because ALK rearrangement status
has been rarely determined at the time of excision of the
primary lesion. Nonetheless, ALK IHC testing in lung cancer
remains challenging because of the relatively low level of
ALK transcription, few data about the sensitivity or specificity
of the test, and the absence of a universally accepted and
evidence-based IHC scoring algorithm to predict ALK rear-
rangement using FISH.4,7–9,11,14 We established ALK IHC
interpretation guideline for screening ALK rearranged NSCLC
patients, named Chung’s SNUBH ALK protocol (Figure 3),10
and we semiquantitatively evaluated ALK rearrangement using
IHC and correlated the results with results obtained using CISH
and FISH in this study.
We also found a high concordance between CISH and
IHC (Table 4). In particular, a different ALK gene arrange-
ment status was observed in tumor cells showing different
IHC score. It is possible because that CISH permits easier
identification of invasive tumor cells and histologic pattern
and correlation with IHC pattern.
IHC to detect protein overexpression on the tumor
cytoplasm and FISH to detect ALK gene rearrangement are
the most frequently used methods in the laboratory. Because
the incidence of ALK rearrangement in NSCLC is relatively
low, it is difficult to use CISH or FISH on all the biopsied or
archived NSCLC samples. Therefore, the development of a
screening method to identify ALK-rearranged tumors is im-
perative, and the diagnostic test needs to be applicable to
archived, formalin-fixed tissues that have been removed sev-
eral years earlier. Because IHC is readily available in pathol-
ogy laboratories, it is important to optimize the condition of
ALK IHC assay as a screening method and to establish an
interpretation guideline.
In this study, we observed a good correlation between
results obtained using IHC and CISH/FISH in a large-scale,
single-institution study using a semiquantitative IHC scoring
assessment. We also presented a diagnostic algorithm to
screen for NSCLC with ALK rearrangements using IHC,
modified Chung’s SNUBH ALK protocol (Figure 3).10 IHC
detection of ALK protein can be affected by a number of
factors including variations in antigen retrieval and tissue
fixatives and fixation methods, varying sensitivities of re-
agents, false-positive and false-negative results, and subjec-
tivity in evaluation of staining intensity. The FISH assay is
relatively expensive compared with IHC and requires expert
interpreter and rapid fadeout of signals, making it somewhat
impractical for routine workflow. These limitations of IHC
and FISH can be overcome by using automated dual-color
CISH with high concordance. We conclude that the CISH can
be used for alternative detection method for ALK gene rear-
rangement and it is a reliable method that has additional
practical benefits suitable for routine diagnostic practice.
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